Skip to content
10-Q

Quarterly Report

TFF PHARMACEUTICALS, INC.

0001213900-24-042918

← back to feed
Filed
May 14, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 13, 2024 3.1M sh
Shares Diluted Q1 2024 · Mar 31, 2024 2.39M sh
Shares Diluted restated Q1 2024 · Mar 31, 2023 1.45M sh
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$3.14M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$4.37M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $3.21M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $5.48M
Stockholders Equity Q1 2024 · Mar 31, 2024 $5.3M
Stockholders Equity Q1 2024 · Dec 31, 2023 $9.57M
Stockholders Equity Q1 2024 · Mar 31, 2023 $16.54M
Stockholders Equity Q1 2024 · Dec 31, 2022 $22.88M
Current Liabilities Q1 2024 · Mar 31, 2024 $3.87M
Current Liabilities Q1 2024 · Dec 31, 2023 $2.43M
Total Liabilities Q1 2024 · Mar 31, 2024 $3.88M
Total Liabilities Q1 2024 · Dec 31, 2023 $2.46M
Current Assets Q1 2024 · Mar 31, 2024 $4.86M
Current Assets Q1 2024 · Dec 31, 2023 $7.59M
Total Assets Q1 2024 · Mar 31, 2024 $9.19M
Total Assets Q1 2024 · Dec 31, 2023 $12.03M
Eps Diluted Q1 2024 · Mar 31, 2024 −$2.40
Eps Diluted restated Q1 2024 · Mar 31, 2023 −$4.87
Eps Basic Q1 2024 · Mar 31, 2024 −$2.40
Eps Basic restated Q1 2024 · Mar 31, 2023 −$4.87
Sga Expense Q1 2024 · Mar 31, 2024 $2.44M
Sga Expense Q1 2024 · Mar 31, 2023 $3.12M
Rd Expense Q1 2024 · Mar 31, 2024 $3.56M
Rd Expense restated Q1 2024 · Mar 31, 2023 $4.02M
Net Income Q1 2024 · Mar 31, 2024 −$5.74M
Net Income Q1 2024 · Mar 31, 2023 −$7.05M
Operating Income Q1 2024 · Mar 31, 2024 −$5.79M
Operating Income Q1 2024 · Mar 31, 2023 −$7.09M
Revenue Q1 2024 · Mar 31, 2024 $203.27K
Revenue Q1 2024 · Mar 31, 2023 $51.43K